Core Viewpoint - Kangzheng Pharmaceutical (00867.HK) announced that its subsidiary, Demy Pharmaceutical Co., Ltd., is applying for an independent listing on the Hong Kong Stock Exchange, focusing on innovative medicines for skin health [1] Group 1: Clinical Trial Results - The Phase III clinical trial of the product, Lurcatinib Cream, for treating mild to moderate Atopic Dermatitis (AD) in China has shown positive results [1] - The trial involved 192 patients and was a randomized, double-blind, placebo-controlled, multi-center study led by Shanghai Skin Disease Hospital [1] - The primary endpoint was significantly achieved, with 63.0% of patients treated with Lurcatinib Cream reaching an Investigator's Global Assessment (IGA) score of 0 or 1 after 8 weeks, compared to 9.2% in the placebo group (P<0.001) [2] - A key secondary endpoint was also met, with 78.0% of patients achieving at least a 75% improvement in the Eczema Area and Severity Index (EASI75) score, compared to 15.4% in the placebo group (P<0.001) [2] Group 2: Safety and Tolerability - The treatment was generally well-tolerated, with most treatment-emergent adverse events (TEAEs) being mild or moderate in severity [2] - No TEAEs led to the discontinuation of the study drug, indicating good overall safety and tolerability [2]
康哲药业(00867.HK)创新药磷酸芦可替尼乳膏AD适应症中国三期药物临床研究取得积极结果